Home » Newsletters » BioWorld Science

BioWorld Science

May 31, 2022

View Archived Issues

Novel tricyclic HIV-1 integrase-LEDGF/p75 allosteric inhibitors show improved antiviral activity

Discovery of novel orally bioavailable SERD with enhanced pharmacological properties

NRG Therapeutics receives Biomedical Catalyst award for neurodegenerative disorders

Glycoengineering improves the anti-inflammatory effects of small extracellular vesicles

SLC13A5 inhibitors identified at the Rosalind Franklin University of Medicine and Science

Suzhou Yabao Pharmaceutical Research and Development patents mutant LRRK2 inhibitors

New menin/MLL interaction inhibitors synthesized at Shanghai Euregen Biopharma

Boehringer Ingelheim presents new indoleamine 2,3-dioxygenase 1 inhibitors

New CD73 inhibitors patented by Humanwell Healthcare

PharmEnable and Denali Therapeutics to collaborate in neurodegenerative disease research

RAGE-silencing RNAi suppresses pulmonary allergic inflammation

Cytoplasmic RNA vector expressing anti-CD81 antibodies suppresses experimental arthritis

Studies identify chronic pain mechanisms in skin and spinal cord

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...